Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Overview
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Companies Involved in Therapeutics Development
Avanti Biosciences Inc
Car Biosciences Inc
Felicitex Therapeutics Inc
KinoPharma Inc
ManRos Therapeutics
Neuroscent Inc
Pharmasum Therapeutics AS
Samumed LLC
San Biotechnology Co Ltd
Voronoi
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Drug Profiles
ABI-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABI-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYR-219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-1610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-7742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-8553 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-9847 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPO-1143 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorecivivint - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-07883 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate DYRK1A for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DYRK1A for Parkinson’s Disease and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRN-024219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dormant Products
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Discontinued Products
Dual Specificity Tyrosine Phosphorylation Regulated Kise 1A (Serine/Threonine Kise MNB or MNB/DYRK Protein Kise or Dual specificity YAK1 Related Kise or HP86 or Protein Kise Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Product Development Milestones
Featured News & Press Releases
Nov 13, 2019: Samumed presents safety data alysis of lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
Jul 18, 2019: Samumed announces publication of preclinical data demonstrating that SM07883 is a potential treatment for alzheimer’s disease
Jun 19, 2019: Samumed doses first subject in phase 3 STRIDES-X-ray trial of lorecivivint for the treatment of knee osteoarthritis
May 02, 2019: Samumed launches phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
Apr 10, 2019: Samumed announces multiple presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Apr 04, 2019: Samumed doses first subject in phase 1 trial of SM07883, a potential treatment for Alzheimer’s Disease
Mar 07, 2019: Samumed to present clinical data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Feb 28, 2019: Samumed announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in knee osteoarthritis
Jan 29, 2019: Samumed to present novel biological targets of SM04690 for treatment of knee osteoarthritis
Nov 05, 2018: Samumed announces multiple presentations at 6th world congress on controversies, debates & consensus in bone, muscle & joint diseases.
Oct 24, 2018: Samumed phase 2b trial in knee osteoarthritis meets primary endpoints
Oct 18, 2018: Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Congress
Oct 16, 2018: Samumed to present data from phase 2b trial of SM04690 for treatment of knee osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting
Jul 27, 2018: Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association Intertiol Conference
Jul 17, 2018: Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer’s Disease Candidate, at the Alzheimer’s Association Intertiol Conference 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Avanti Biosciences Inc, H2 2019
Pipeline by Carna Biosciences Inc, H2 2019
Pipeline by Felicitex Therapeutics Inc, H2 2019
Pipeline by KinoPharma Inc, H2 2019
Pipeline by ManRos Therapeutics, H2 2019
Pipeline by NeuroNascent Inc, H2 2019
Pipeline by Pharmasum Therapeutics AS, H2 2019
Pipeline by Samumed LLC, H2 2019
Pipeline by San Biotechnology Co Ltd, H2 2019
Pipeline by Voronoi, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019